AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Annexin A5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P08758

UPID:

ANXA5_HUMAN

Alternative names:

Anchorin CII; Annexin V; Annexin-5; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Placental anticoagulant protein I; Thromboplastin inhibitor; Vascular anticoagulant-alpha

Alternative UPACC:

P08758; D3DNW7; Q6FHB3; Q6FI16; Q8WV69; Q9UDH9

Background:

Annexin A5, known by various names such as Annexin V, Placental anticoagulant protein I, and Vascular anticoagulant-alpha, plays a pivotal role in the blood coagulation cascade. It acts as an indirect inhibitor of the thromboplastin-specific complex, showcasing its anticoagulant properties.

Therapeutic significance:

Given its involvement in recurrent pregnancy loss, a condition marked by spontaneous abortion before 24 weeks of gestation, Annexin A5's study is crucial. Understanding the role of Annexin A5 could open doors to potential therapeutic strategies for managing this pregnancy complication.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.